Virus vs. superbug: experimental treatment targets deadly hospital pneumonia
NCT ID NCT07202234
Summary
This study is testing whether a cocktail of bacteriophages—viruses that target specific bacteria—can safely and effectively treat ventilator-associated pneumonia caused by drug-resistant bacteria. The trial will enroll 248 hospitalized adult patients who have developed this serious infection while on a breathing machine. Researchers will compare the phage therapy to standard care to see if it improves recovery, clears the infection faster, and reduces hospital stays.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VAP - VENTILATOR ASSOCIATED PNEUMONIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.